Статті в журналах: "Therapeutic potential of anticancer immunotoxins"

1

Choudhary, Swati, Mrudula Mathew, and Rama S. Verma. "Therapeutic potential of anticancer immunotoxins." Drug Discovery Today 16, no. 11-12 (June 2011): 495–503. http://dx.doi.org/10.1016/j.drudis.2011.04.003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Ahmad, Zuhaida Asra, Swee Keong Yeap, Abdul Manaf Ali, Wan Yong Ho, Noorjahan Banu Mohamed Alitheen, and Muhajir Hamid. "scFv Antibody: Principles and Clinical Application." Clinical and Developmental Immunology 2012 (2012): 1–15. http://dx.doi.org/10.1155/2012/980250.

Повний текст джерела

Анотація:

To date, generation of single-chain fragment variable (scFv) has become an established technique used to produce a completely functional antigen-binding fragment in bacterial systems. The advances in antibody engineering have now facilitated a more efficient and generally applicable method to produce Fv fragments. Basically, scFv antibodies produced from phage display can be genetically fused to the marker proteins, such as fluorescent proteins or alkaline phosphatase. These bifunctional proteins having both antigen-binding capacity and marker activity can be obtained from transformed bacteria and used for one-step immunodetection of biological agents. Alternatively, antibody fragments could also be applied in the construction of immunotoxins, therapeutic gene delivery, and anticancer intrabodies for therapeutic purposes. This paper provides an overview of the current studies on the principle, generation, and application of scFv. The potential of scFv in breast cancer research is also discussed in this paper.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Oszajca, Katarzyna, Łukasz Wieteska, Magdalena Cybula, and Janusz Szemraj. "The assessment of prokaryotic addictive modules’ activity in the context of seeking novel immunotoxins." Postępy Polskiej Medycyny i Farmacji 5 (June 26, 2017): 59–63. http://dx.doi.org/10.5604/01.3001.0011.6195.

Повний текст джерела

Анотація:

Despite of the fact that current anticancer chemotherapeutics have many beneficial achievements, there is an urgent need for new efficient therapies. A new type of drugs which are extensively investigated are immunotoxinshybrid proteins that consist of cytotoxic component and second part which is responsible for selective binding to the receptors on tumor cells. Unfortunately, this group of therapeutics still has many drawbacks. There is a strong demand for research on a new substances and develo-ping targeted therapy strategies. In the present study we tested VapC toxin derived from prokaryotic addictive modules as a potential component in the construction of immunotoxins. Investigated fusion protein consists of VapC toxin has RNase activity and digests total RNA in various treatment times. Moreover, studied protein displays proapoptotic properties and cell cycle arrest in selected cancer cell lines.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Stone, Marvin J. "Immunotoxins as Potential Anticancer Agents." Baylor University Medical Center Proceedings 3, no. 4 (October 1990): 35–37. http://dx.doi.org/10.1080/08998280.1990.11929736.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Pincus, Seth H. "Therapeutic potential of anti-HIV immunotoxins." Antiviral Research 33, no. 1 (October 1996): 1–9. http://dx.doi.org/10.1016/s0166-3542(96)00995-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Kawakami, Koji, Oumi Nakajima, Ryuichi Morishita, and Ryozo Nagai. "Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties." Scientific World JOURNAL 6 (2006): 781–90. http://dx.doi.org/10.1100/tsw.2006.162.

Повний текст джерела

Анотація:

Despite the progress of the bioinformatics approach to characterize cell-surface antigens and receptors on tumor cells, it remains difficult to generate novel cancer vaccines or neutralizing monoclonal antibody therapeutics. Among targeted cancer therapeutics, biologicals with targetable antibodies or ligands conjugated or fused to toxins or chemicals for direct cell-killing ability have been developed over the last 2 decades. These conjugated or fused chimeric proteins are termed immunotoxins or cytotoxic agents. Two agents, DAB389IL-2 (ONTAKTM) targeting the interleukin-2 receptor and CD33-calicheamicin (Mylotarg®), have been approved by the FDA for cutaneous T-cell lymphoma (CTCL) and relapsed acute myeloid leukemia (AML), respectively. Such targetable agents, including RFB4(dsFv)-PE38 (BL22), IL13-PE38QQR, and Tf-CRM107, are being tested in clinical trials. Several agents using unique technology such as a cleavable adapter or immunoliposomes with antibodies are also in the preclinical stage. This review summarizes the generation, mechanism, and development of these agents. In addition, possible future directions of this therapeutic approach are discussed.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Weldon, John E., Laiman Xiang, Oleg Chertov, Inger Margulies, Robert J. Kreitman, David J. FitzGerald, and Ira Pastan. "A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity." Blood 113, no. 16 (April 16, 2009): 3792–800. http://dx.doi.org/10.1182/blood-2008-08-173195.

Повний текст джерела

Анотація:

Abstract Immunotoxins based on Pseudomonas exotoxin A (PE) are promising anticancer agents that combine a variable fragment (Fv) from an antibody to a tumor-associated antigen with a 38-kDa fragment of PE (PE38). The intoxication pathway of PE immunotoxins involves receptor-mediated internalization and trafficking through endosomes/lysosomes, during which the immunotoxin undergoes important proteolytic processing steps but must otherwise remain intact for eventual transport to the cytosol. We have investigated the proteolytic susceptibility of PE38 immunotoxins to lysosomal proteases and found that cleavage clusters within a limited segment of PE38. We subsequently generated mutants containing deletions in this region using HA22, an anti-CD22 Fv-PE38 immunotoxin currently undergoing clinical trials for B-cell malignancies. One mutant, HA22-LR, lacks all identified cleavage sites, is resistant to lysosomal degradation, and retains excellent biologic activity. HA22-LR killed chronic lymphocytic leukemia cells more potently and uniformly than HA22, suggesting that lysosomal protease digestion may limit immunotoxin efficacy unless the susceptible domain is eliminated. Remarkably, mice tolerated doses of HA22-LR at least 10-fold higher than lethal doses of HA22, and these higher doses exhibited markedly enhanced antitumor activity. We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Narbona, Javier, Rubén G. Gordo, Jaime Tomé-Amat та Javier Lacadena. "A New Optimized Version of a Colorectal Cancer-Targeted Immunotoxin Based on a Non-Immunogenic Variant of the Ribotoxin α-Sarcin". Cancers 15, № 4 (9 лютого 2023): 1114. http://dx.doi.org/10.3390/cancers15041114.

Повний текст джерела

Анотація:

Due to its incidence and mortality, cancer remains one of the main risks to human health and lifespans. In order to overcome this worldwide disease, immunotherapy and the therapeutic use of immunotoxins have arisen as promising approaches. However, the immunogenicity of foreign proteins limits the dose of immunotoxins administered, thereby leading to a decrease in its therapeutic benefit. In this study, we designed two different variants of non-immunogenic immunotoxins (IMTXA33αSDI and IMTXA33furαSDI) based on a deimmunized variant of the ribotoxin α-sarcin. The inclusion of a furin cleavage site in IMTXA33furαSDI would allow a more efficient release of the toxic domain to the cytosol. Both immunotoxins were produced and purified in the yeast Pichia pastoris and later functionally characterized (both in vitro and in vivo), and immunogenicity assays were carried out. The results showed that both immunotoxins were functionally active and less immunogenic than the wild-type immunotoxin. In addition, IMTXA33furαSDI showed a more efficient antitumor effect (both in vitro and in vivo) due to the inclusion of the furin linker. These results constituted a step forward in the optimization of immunotoxins with low immunogenicity and enhanced antitumor activity, which can lead to potential better outcomes in cancer treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Balalaeva, I. V., E. A. Sokolova, A. D. Puzhikhina, A. A. Brilkina, and S. M. Deyev. "Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro." Acta Naturae 9, no. 1 (March 15, 2017): 38–44. http://dx.doi.org/10.32607/20758251-2017-9-1-38-44.

Повний текст джерела

Анотація:

Tumor response to therapeutic treatment is largely determined by its heterogeneity and the presence of intercellular junctions, hindering the penetration of large molecules deep into the three-dimensional structure of the tumor. In that context, 3D in vitro tumor models such as cancer cell spheroids are becoming increasingly popular. We obtained spheroids of human breast adenocarcinoma SKBR-3 overexpressing the HER2 cancer marker. The toxicity of HER2-targeted immunotoxin 4D5scFv-PE40 against spheroids was shown to be several orders of magnitude lower compared to a monolayer cell culture. The significant difference in the severity of the immunotoxin effect can be explained by the fact that it ineffectively penetrates the spheroid and predominantly influences the cells of the outer layers. The resulting tumor spheroid model can be used in development of drugs for targeted therapy as well as to study ways to improve the efficiency of anticancer agents by targeting cell-cell contacts.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Ruiz-de-la-Herrán, Javier, Jaime Tomé-Amat, Rodrigo Lázaro-Gorines, José G. Gavilanes та Javier Lacadena. "Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins". Toxins 11, № 10 (12 жовтня 2019): 593. http://dx.doi.org/10.3390/toxins11100593.

Повний текст джерела

Анотація:

Immunotoxins are chimeric molecules that combine the specificity of an antibody to recognize and bind tumor antigens with the potency of the enzymatic activity of a toxin, thus, promoting the death of target cells. Among them, RNases-based immunotoxins have arisen as promising antitumor therapeutic agents. In this work, we describe the production and purification of two new immunoconjugates, based on RNase T1 and the fungal ribotoxin α-sarcin, with optimized properties for tumor treatment due to the inclusion of a furin cleavage site. Circular dichroism spectroscopy, ribonucleolytic activity studies, flow cytometry, fluorescence microscopy, and cell viability assays were carried out for structural and in vitro functional characterization. Our results confirm the enhanced antitumor efficiency showed by these furin-immunotoxin variants as a result of an improved release of their toxic domain to the cytosol, favoring the accessibility of both ribonucleases to their substrates. Overall, these results represent a step forward in the design of immunotoxins with optimized properties for potential therapeutic application in vivo.

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Sanz, Laura, Raquel Ibáñez-Pérez, Patricia Guerrero-Ochoa, Javier Lacadena, and Alberto Anel. "Antibody-Based Immunotoxins for Colorectal Cancer Therapy." Biomedicines 9, no. 11 (November 19, 2021): 1729. http://dx.doi.org/10.3390/biomedicines9111729.

Повний текст джерела

Анотація:

Monoclonal antibodies (mAbs) are included among the treatment options for advanced colorectal cancer (CRC). However, while these mAbs effectively target cancer cells, they may have limited clinical activity. A strategy to improve their therapeutic potential is arming them with a toxic payload. Immunotoxins (ITX) combining the cell-killing ability of a toxin with the specificity of a mAb constitute a promising strategy for CRC therapy. However, several important challenges in optimizing ITX remain, including suboptimal pharmacokinetics and especially the immunogenicity of the toxin moiety. Nonetheless, ongoing research is working to solve these limitations and expand CRC patients’ therapeutic armory. In this review, we provide a comprehensive overview of targets and toxins employed in the design of ITX for CRC and highlight a wide selection of ITX tested in CRC patients as well as preclinical candidates.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Lee, Ji Won, Hyun Jung Kim, and Kyun Heo. "Therapeutic aptamers: developmental potential as anticancer drugs." BMB Reports 48, no. 4 (April 30, 2015): 234–37. http://dx.doi.org/10.5483/bmbrep.2015.48.4.277.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Toole, Bryan, Shibnath Ghatak, and Suniti Misra. "Hyaluronan Oligosaccharides as a Potential Anticancer Therapeutic." Current Pharmaceutical Biotechnology 9, no. 4 (August 1, 2008): 249–52. http://dx.doi.org/10.2174/138920108785161569.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Panigrahy, Dipak, Lucy Q. Shen, Mark W. Kieran, and Arja Kaipainen. "Therapeutic potential of thiazolidinediones as anticancer agents." Expert Opinion on Investigational Drugs 12, no. 12 (December 2003): 1925–37. http://dx.doi.org/10.1517/13543784.12.12.1925.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Ying, Hua-Zhong, Chen-Huan Yu, Hao-Kun Chen, Huan-Huan Zhang, Jie Fang, Fang Wu, and Wen-Ying Yu. "Quinonoids: Therapeutic Potential for Lung Cancer Treatment." BioMed Research International 2020 (April 7, 2020): 1–13. http://dx.doi.org/10.1155/2020/2460565.

Повний текст джерела

Анотація:

Lung cancer is the leading cause of cancer-related deaths worldwide. Owing to its high incidence and mortality, the development and discovery of novel anticancer drugs is of great importance. In recent years, many breakthroughs have been achieved in the search for effective anticancer substances from natural products. Many anticancer drugs used clinically and proven to be effective are derived from natural products. Quinonoids, including naphthoquinones, phenanthrenequinones, benzoquinones, and anthraquinones, constitute a large group of natural bioactive compounds that widely exist in higher and lower plant species. Given that most of these compounds possess anticancer effects, they are applied in many cancer studies, especially in lung cancer research. They can promote apoptosis, induce autophagy, and inhibit proliferation, angiogenesis, and cell invasion and migration. Some drugs can enhance anticancer effects when combined with other drugs. Thus, quinonoids have broad application prospects in the treatment of lung cancer. Here, we summarize the previous studies on the antilung cancer activities of quinonoids together with their underlying mechanisms and analyze the common research targets with different effects so as to provide references for the discovery of quinonoids against lung cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Guerrero-Ochoa, Patricia, Raquel Ibáñez-Pérez, Germán Berbegal-Pinilla, Diederich Aguilar, Isabel Marzo, Francisco Corzana, Martha Minjárez-Sáenz, et al. "Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment." Biomedicines 10, no. 6 (May 24, 2022): 1223. http://dx.doi.org/10.3390/biomedicines10061223.

Повний текст джерела

Анотація:

Two granulysin (GRNLY) based immunotoxins were generated, one containing the scFv of the SM3 mAb (SM3GRNLY) and the other the scFv of the AR20.5 mAb (AR20.5GRNLY). These mAb recognize different amino acid sequences of aberrantly O-glycosylated MUC1, also known as the Tn antigen, expressed in a variety of tumor cell types. We first demonstrated the affinity of these immunotoxins for their antigen using surface plasmon resonance for the purified antigen and flow cytometry for the antigen expressed on the surface of living tumor cells. The induction of cell death of tumor cell lines of different origin positive for Tn antigen expression was stronger in the cases of the immunotoxins than that induced by GRNLY alone. The mechanism of cell death induced by the immunotoxins was studied, showing that the apoptotic component demonstrated previously for GRNLY was also present, but that cell death induced by the immunotoxins included also necroptotic and necrotic components. Finally, we demonstrated the in vivo tumor targeting by the immunotoxins after systemic injection using a xenograft model of the human pancreatic adenocarcinoma CAPAN-2 in athymic mice. While GRNLY alone did not have a therapeutic effect, SM3GRNLY and AR20.5GRNLY reduced tumor volume by 42 and 60%, respectively, compared with untreated tumor-bearing mice, although the results were not statistically significant in the case of AR20.5GRNLY. Histological studies of tumors obtained from treated mice demonstrated reduced cellularity, nuclear morphology compatible with apoptosis induction and active caspase-3 detection by immunohistochemistry. Overall, our results exemplify that these immunotoxins are potential drugs to treat Tn-expressing cancers.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Çetinkaya, Melisa, and Yusuf Baran. "Therapeutic Potential of Luteolin on Cancer." Vaccines 11, no. 3 (February 27, 2023): 554. http://dx.doi.org/10.3390/vaccines11030554.

Повний текст джерела

Анотація:

Cancer is a global concern, as the rate of incidence is increasing each year. The challenges related to the current chemotherapy drugs, such as the concerns related to toxicity, turn to cancer therapeutic research to discover alternative therapy strategies that are less toxic to normal cells. Among those studies, the use of flavonoids—natural compounds produced by plants as secondary metabolites for cancer therapy—has been a hot topic in cancer treatment. Luteolin, a flavonoid that has been present in many fruits, vegetables, and herbs, has been identified to exhibit numerous biological activities, including anti-inflammatory, antidiabetic, and anticancer properties. The anticancer property of Luteolin has been extensively researched in many cancer types and has been related to its ability to inhibit tumor growth by targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression. It achieves this by interacting with various signaling pathways and proteins. In the current review, the molecular targets of Luteolin as it exerts its anticancer properties, the combination therapy that includes Luteolin with other flavonoids or chemotherapeutic drugs, and the nanodelivery strategies for Luteolin are described for several cancer types.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Ahmed, Salman, Haroon Khan, Michael Aschner, Hamed Mirzae, Esra Küpeli Akkol, and Raffaele Capasso. "Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects." International Journal of Molecular Sciences 21, no. 16 (August 6, 2020): 5622. http://dx.doi.org/10.3390/ijms21165622.

Повний текст джерела

Анотація:

Cancer is one of the most extreme medical conditions in both developing and developed countries around the world, causing millions of deaths each year. Chemotherapy and/or radiotherapy are key for treatment approaches, but both have numerous adverse health effects. Furthermore, the resistance of cancerous cells to anticancer medication leads to treatment failure. The rising burden of cancer overall requires novel efficacious treatment modalities. Natural medications offer feasible alternative options against malignancy in contrast to western medication. Furanocoumarins’ defensive and restorative impacts have been observed in leukemia, glioma, breast, lung, renal, liver, colon, cervical, ovarian, and prostate malignancies. Experimental findings have shown that furanocoumarins activate multiple signaling pathways, leading to apoptosis, autophagy, antioxidant, antimetastatic, and cell cycle arrest in malignant cells. Additionally, furanocoumarins have been shown to have chemo preventive and chemotherapeutic synergistic potential when used in combination with other anticancer drugs. Here, we address different pathways which are activated by furanocoumarins and their therapeutic efficacy in various tumors. Ideally, this review will trigger interest in furanocoumarins and their potential efficacy and safety as a cancer lessening agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Bolhassani, Azam, and Farnaz Zahedifard. "Therapeutic live vaccines as a potential anticancer strategy." International Journal of Cancer 131, no. 8 (June 20, 2012): 1733–43. http://dx.doi.org/10.1002/ijc.27640.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Tovmasyan, Artak, Romulo S. Sampaio, Mary-Keara Boss, Jacqueline C. Bueno-Janice, Bader H. Bader, Milini Thomas, Julio S. Reboucas, et al. "Anticancer therapeutic potential of Mn porphyrin/ascorbate system." Free Radical Biology and Medicine 89 (December 2015): 1231–47. http://dx.doi.org/10.1016/j.freeradbiomed.2015.10.416.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Nandini, Pathak, Rani Anju, Singh Chhaya, Chauhan Neha, and Singh Raj. "Fermented Foods: The Pharmacological and Anticancer Therapeutic Potential." International Journal of Zoological Investigations 08, no. 02 (2022): 613–22. http://dx.doi.org/10.33745/ijzi.2022.v08i02.075.

Повний текст джерела

Анотація:

Globally, dietary and environmental changes have been recognized as major causes of noncommunicable diseases such as malignancies, with ongoing research on modifiable risk factors, including eating habits, estimating that 30–40% of cancer formation can be avoided with behavioral adjustments. According to estimates from the World Health Organization (WHO), cancer is the second leading cause of death worldwide, with 9.6 million fatalities projected in 2018. Cancer accounts for nearly 1 in every 6 deaths especially in females. In a survey of year 2019 within Indian subcontinent about 20% (one in five) female suffers from one of the symptoms of ovarian disorders which further turns into tumors such as ovarian epithelial cells, endometriosis. More effective cancer treatments with lower toxicity are required. Natural foods have become increasingly popular in the treatment and prevention of cancer. Some nutrient components in fermented foods are referred to be "naturally fortified functional nutrients" because they assist to maintain a healthy gut microbiome, which protects against disease and physiology and could prove to be boon for those females by boosting metabolism because such women have lower healthy gut microflora as compared to other females as fermented foods have higher probiotic value which enhance the gut flora. The epidemiological studies suggest the evidences that lactic acid bacteria present in fermented foods plays an important role in preventing breast cancer. This review article summarizes the health benefits of fermented food to certain cancer which has been scientifically proven.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Gallagher, W. J., and M. W. Burk. "Monoclonal antibody-ricin a chain conjugates (immunotoxins): Potential therapeutic agents for human colon carcinoma." Journal of Surgical Research 40, no. 2 (February 1986): 159–66. http://dx.doi.org/10.1016/0022-4804(86)90118-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Lehman, H. P., U. Zangemeister-Wittke, E. J. Wawrzynczak, A. Collinson, R. Waibel, and R. A. Stahel. "Cytotoxicity and therapeutic potential of immunotoxins recognizing different antigens of small cell lung cancer." Lung Cancer 7 (January 1991): 186. http://dx.doi.org/10.1016/0169-5002(91)92044-j.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Bannu, Saira M., Dakshayani Lomada, Surendra Gulla, Thummala Chandrasekhar, Pallu Reddanna, and Madhava C. Reddy. "Potential Therapeutic Applications of C-Phycocyanin." Current Drug Metabolism 20, no. 12 (January 20, 2020): 967–76. http://dx.doi.org/10.2174/1389200220666191127110857.

Повний текст джерела

Анотація:

Background: Cancer and other disorders such as inflammation, autoimmune diseases and diabetes are the major health problems observed all over the world. Therefore, identifying a therapeutic target molecule for the treatment of these diseases is urgently needed to benefit public health. C-Phycocyanin (C-PC) is an important light yielding pigment intermittently systematized in the cyanobacterial species along with other algal species. It has numerous applications in the field of biotechnology and drug industry and also possesses antioxidant, anticancer, antiinflammatory, enhanced immune function, including liver and kidney protection properties. The molecular mechanism of action of C-PC for its anticancer activity could be the blockage of cell cycle progression, inducing apoptosis and autophagy in cancer cells. Objectives: The current review summarizes an update on therapeutic applications of C-PC, its mechanism of action and mainly focuses on the recent development in the field of C-PC as a drug that exhibits beneficial effects against various human diseases including cancer and inflammation. Conclusion: he data from various studies suggest the therapeutic applications of C-PC such as anti-cancer activity, anti-inflammation, anti-angiogenic activity and healing capacity of certain autoimmune disorders. Mechanism of action of C-PC for its anticancer activity is the blockage of cell cycle progression, inducing apoptosis and autophagy in cancer cells. The future perspective of C-PC is to identify and define the molecular mechanism of its anti-cancer, anti-inflammatory and antioxidant activities, which would shed light on our knowledge on therapeutic applications of C-PC and may contribute significant benefits to global public health.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Hussain, Hidayat, Ivan R. Green, Muhammad Saleem, Muhammad Liaquat Raza, and Mamona Nazir. "Therapeutic Potential of Iridoid Derivatives: Patent Review." Inventions 4, no. 2 (May 16, 2019): 29. http://dx.doi.org/10.3390/inventions4020029.

Повний текст джерела

Анотація:

Iridoids belong to a family of monoterpenoids comprising the cyclopentan[c]-pyran system; this class of compounds offers a wide range of biological effects, namely antileishmanial, anticancer, antiplasmodial, and anti-inflammatory potency. To date, a large number of biologically active iridoid derivatives have been reported from various plant families, including Rubiaceae, Plantaginaceae, Scrophulariaceae, and Verbenaceae. Furthermore, iridoids have the potential to form conjugates with other anticancer, antidiabetic, antileishmanial, and antimalarial drugs which synergistically have the potential to increase their effects. Additionally, future research should focus on the synthesis of halo analogs as well as preparing homo dimers or heterodimers of iridoids, since these might quite conceivably possess an increased bioactivity.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Aaghaz, Shams, Vivek Gohel, and Ahmed Kamal. "Peptides as Potential Anticancer Agents." Current Topics in Medicinal Chemistry 19, no. 17 (September 19, 2019): 1491–511. http://dx.doi.org/10.2174/1568026619666190125161517.

Повний текст джерела

Анотація:

Cancer consists of heterogeneous multiple cell subpopulation which at a later stage develop resistant phenotypes, which include resistance to pro-apoptotic stimuli and/or cytotoxic resistance to anticancer compounds. The property of cancerous cells to affect almost any part of the body categorizes cancer to many anatomic and molecular subtypes, each requiring a particular therapeutic intervention. As several modalities are hindered in a variety of cancers and as the cancer cells accrue varied types of oncogenic mutations during their progression the most likely benefit will be obtained by a combination of therapeutic agents that might address the diverse hallmarks of cancer. Natural compounds are the backbone of cancer therapeutics owing to their property of affecting the DNA impairment and restoration mechanisms and also the gene expression modulated via several epigenetic molecular mechanisms. Bioactive peptides isolated from flora and fauna have transformed the arena of antitumour therapy and prompt progress in preclinical studies is promising. The difficulties in creating ACP rest in improving its delivery to the tumour site and it also must maintain a low toxicity profile. The substantial production costs, low selectivity and proteolytic stability of some ACP are some of the factors hindering the progress of peptide drug development. Recently, several publications have tried to edify the field with the idea of using peptides as adjuvants with established drugs for antineoplastic use. This review focuses on peptides from natural sources that precisely target tumour cells and subsequently serve as anticancer agents that are less toxic to normal tissues.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Hagerty, Brendan L., Guillaume J. Pegna, Jian Xu, Chin-Hsien Tai, and Christine Alewine. "Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors." Biomolecules 10, no. 7 (June 28, 2020): 973. http://dx.doi.org/10.3390/biom10070973.

Повний текст джерела

Анотація:

Mesothelin (MSLN) is a cell surface glycoprotein normally expressed only on serosal surfaces, and not found in the parenchyma of vital organs. Many solid tumors also express MSLN, including mesothelioma and pancreatic adenocarcinoma. Due to this favorable expression profile, MSLN represents a viable target for directed anti-neoplastic therapies, such as recombinant immunotoxins (iToxs). Pre-clinical testing of MSLN-targeted iTox’s has yielded a strong body of evidence for activity against a number of solid tumors. This has led to multiple clinical trials, testing the safety and efficacy of the clinical leads SS1P and LMB-100. While promising clinical results have been observed, neutralizing anti-drug antibody (ADA) formation presents a major challenge to overcome in the therapeutic development process. Additionally, on-target, off-tumor toxicity from serositis and non-specific capillary leak syndrome (CLS) also limits the dose, and therefore, impact anti-tumor activity. This review summarizes existing pre-clinical and clinical data on MSLN-targeted iTox’s. In addition, we address the potential future directions of research to enhance the activity of these anti-tumor agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Szczepanek, Joanna, Monika Skorupa, and Andrzej Tretyn. "MicroRNA as a Potential Therapeutic Molecule in Cancer." Cells 11, no. 6 (March 16, 2022): 1008. http://dx.doi.org/10.3390/cells11061008.

Повний текст джерела

Анотація:

Small noncoding RNAs, as post-translational regulators of many target genes, are not only markers of neoplastic disease initiation and progression, but also markers of response to anticancer therapy. Hundreds of miRNAs have been identified as biomarkers of drug resistance, and many have demonstrated the potential to sensitize cancer cells to therapy. Their properties of modulating the response of cells to therapy have made them a promising target for overcoming drug resistance. Several methods have been developed for the delivery of miRNAs to cancer cells, including introducing synthetic miRNA mimics, DNA plasmids containing miRNAs, and small molecules that epigenetically alter endogenous miRNA expression. The results of studies in animal models and preclinical studies for solid cancers and hematological malignancies have confirmed the effectiveness of treatment protocols using microRNA. Nevertheless, the use of miRNAs in anticancer therapy is not without limitations, including the development of a stable nanoconstruct, delivery method choices, and biodistribution. The aim of this review was to summarize the role of miRNAs in cancer treatment and to present new therapeutic concepts for these molecules. Supporting anticancer therapy with microRNA molecules has been verified in numerous clinical trials, which shows great potential in the treatment of cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Mezo, Gabor, Marilena Manea, Ildiko Szabo, Borbala Vincze, and Magdolna Kovacs. "New Derivatives of GnRH as Potential Anticancer Therapeutic Agents." Current Medicinal Chemistry 15, no. 23 (October 1, 2008): 2366–79. http://dx.doi.org/10.2174/092986708785909157.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Kamran, Sareh, Ajantha Sinniah, Mahfoudh A. M. Abdulghani, and Mohammed Abdullah Alshawsh. "Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review." Cancers 14, no. 5 (February 22, 2022): 1100. http://dx.doi.org/10.3390/cancers14051100.

Повний текст джерела

Анотація:

Cancer is a life-threatening disease and is considered to be among the leading causes of death worldwide. Chemoresistance, severe toxicity, relapse and metastasis are the major obstacles in cancer therapy. Therefore, introducing new therapeutic agents for cancer remains a priority to increase the range of effective treatments. Terpenoids, a large group of secondary metabolites, are derived from plant sources and are composed of several isoprene units. The high diversity of terpenoids has drawn attention to their potential anticancer and pharmacological activities. Some terpenoids exhibit an anticancer effect by triggering various stages of cancer progression, for example, suppressing the early stage of tumorigenesis via induction of cell cycle arrest, inhibiting cancer cell differentiation and activating apoptosis. At the late stage of cancer development, certain terpenoids are able to inhibit angiogenesis and metastasis via modulation of different intracellular signaling pathways. Significant progress in the identification of the mechanism of action and signaling pathways through which terpenoids exert their anticancer effects has been highlighted. Hence, in this review, the anticancer activities of twenty-five terpenoids are discussed in detail. In addition, this review provides insights on the current clinical trials and future directions towards the development of certain terpenoids as potential anticancer agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Teixeira, Thaiz Rodrigues, Gustavo Souza dos Santos, Lorene Armstrong, Pio Colepicolo, and Hosana Maria Debonsi. "Antitumor Potential of Seaweed Derived-Endophytic Fungi." Antibiotics 8, no. 4 (October 31, 2019): 205. http://dx.doi.org/10.3390/antibiotics8040205.

Повний текст джерела

Анотація:

The marine environment presents a high biodiversity and a valuable source of bioactive compounds with therapeutic and biotechnological potential. Among the organisms present in marine environment, the endophytic fungi isolated from seaweed stand out. These microorganisms have aroused interest in the scientific community regarding its various activities such as antiviral, antimicrobial, antioxidant, photoprotective, cytotoxic, genotoxic, anti-inflammatory, and anticancer, besides establishing important ecological relations with its hosts. Anticancer molecules derived from marine natural sources are a promising target against different types of cancer. The disease’s high rates of morbidity and mortality affect millions of people world wild and the search for new therapeutic alternatives is needed. Thus, this review partially summarizes the methodologies for the isolation of seaweed-derived endophytic fungi, as well as describes the anticancer compounds isolated from such microorganisms, reported in the literature from 2009 to the present. In addition, it describes how some biotechnological processes can help in the discovery of bioactive compounds, especially with anticancer activity.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Reang, Jurnal, Prabodh Chander Sharma, Vijay Kumar Thakur, and Jaseela Majeed. "Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer." Biomolecules 11, no. 8 (July 31, 2021): 1130. http://dx.doi.org/10.3390/biom11081130.

Повний текст джерела

Анотація:

Cancer, a fatal disease, is also one of the main causes of death worldwide. Despite various developments to prevent and treat cancer, the side effects of anticancer drugs remain a major concern. Ascorbic acid is an essential vitamin required by our bodies for normal physiological function and also has antioxidant and anticancer activity. Although the body cannot synthesize ascorbic acid, it is abundant in nature through foods and other natural sources and also exists as a nutritional food supplement. In anticancer drug development, ascorbic acid has played an important role by inhibiting the development of cancer through various mechanisms, including scavenging reactive oxygen species (ROS), selectively producing ROS and encouraging their cytotoxicity against tumour cells, preventing glucose metabolism, serving as an epigenetic regulator, and regulating the expression of HIF in tumour cells. Several ascorbic acid analogues have been produced to date for their anticancer and antioxidant activity. The current review summarizes the mechanisms behind ascorbic acid's antitumor activity, presents a compilation of its derivatives and their biological activity as anticancer agents, and discusses delivery systems such as liposomes, nanoparticles against cancer, and patents on ascorbic acid as anticancer agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Alven, Sibusiso, Xhamla Nqoro, Buhle Buyana, and Blessing A. Aderibigbe. "Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer." Pharmaceutics 12, no. 5 (April 29, 2020): 406. http://dx.doi.org/10.3390/pharmaceutics12050406.

Повний текст джерела

Анотація:

Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Lombrea, Adelina, Alexandra Denisa Scurtu, Stefana Avram, Ioana Zinuca Pavel, Māris Turks, Jevgeņija Lugiņina, Uldis Peipiņš, Cristina Adriana Dehelean, Codruta Soica, and Corina Danciu. "Anticancer Potential of Betulonic Acid Derivatives." International Journal of Molecular Sciences 22, no. 7 (April 1, 2021): 3676. http://dx.doi.org/10.3390/ijms22073676.

Повний текст джерела

Анотація:

Clinical trials have evidenced that several natural compounds, belonging to the phytochemical classes of alkaloids, terpenes, phenols and flavonoids, are effective for the management of various types of cancer. Latest research has proven that natural products and their semisynthetic variants may serve as a starting point for new drug candidates with a diversity of biological and pharmacological activities, designed to improve bioavailability, overcome cellular resistance, and enhance therapeutic efficacy. This review was designed to bring an update regarding the anticancer potential of betulonic acid and its semisynthetic derivatives. Chemical derivative structures of betulonic acid including amide, thiol, and piperidine groups, exert an amplification of the in vitro anticancer potential of betulonic acid. With the need for more mechanistic and in vivo data, some derivatives of betulonic acids may represent promising anticancer agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Govindaraj, Jayamathi. "A review on the therapeutic potential of Banana flower." Bioinformation 18, no. 4 (April 30, 2022): 349–53. http://dx.doi.org/10.6026/97320630018349.

Повний текст джерела

Анотація:

Banana (Musa paradisiaca) flower is rich in phytochemicals and exhibit antioxidant, anti-inflammatory, anticancer properties etc. The flower extract of banana showed promising therapeutic effects due to the presence of phytochemicals and minerals.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Kronke, M., JM Depper, WJ Leonard, ES Vitetta, TA Waldmann, and WC Greene. "Adult T cell leukemia: a potential target for ricin A chain immunotoxins." Blood 65, no. 6 (June 1, 1985): 1416–21. http://dx.doi.org/10.1182/blood.v65.6.1416.bloodjournal6561416.

Повний текст джерела

Анотація:

Abstract Adult T cell leukemia (ATL) is an almost uniformly fatal malignancy of mature T cells associated with human T cell leukemia/lymphoma virus type 1 (HTLV-1) infection. Cells from this leukemia are characterized by the expression of large numbers of receptors for interleukin 2 (IL- 2). In an attempt to prepare an immunotoxin with selective cytotoxicity for ATL cells, we conjugated anti-Tac, a monoclonal anti-IL-2 receptor antibody, to purified ricin A chains. Although unmodified anti-Tac had no effect on the protein synthesis of these cells, anti-Tac-ricin A chain conjugates produced half-maximal inhibition of protein synthesis in HTLV-1-infected leukemic T cell lines at concentrations of 2 to 6 X 10(-10) mol/L (ID50). An essentially identical ID50 was obtained with leukemic peripheral blood T lymphocytes isolated from two patients with ATL. In contrast, half-maximal inhibition of protein synthesis in HTLV- uninfected, IL-2 receptor-negative T and B cell lines required 200- to 1,000-fold higher concentrations of anti-Tac-ricin A chain conjugates. Both unconjugated anti-Tac and immunoaffinity-purified IL-2 completely inhibited the toxic effects of anti-Tac-ricin A, confirming the specificity of the conjugate-IL-2 receptor interaction. Clonogenic assays demonstrated that anti-Tac-ricin A chain was able to eliminate greater than 99.9% of an HTLV-1-infected T cell population at concentrations only marginally affecting IL-2 receptor-negative cells. The data presented demonstrate that anti-Tac-ricin A is selectively cytotoxic for HTLV-1-infected leukemic T cells in vitro and raises the future possibility of specific therapeutic intervention with immunotoxins in this disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

殷, 方田. "Regulatory T Cells as Potential Therapeutic Targets for Anticancer Therapy." Advances in Clinical Medicine 12, no. 10 (2022): 9267–72. http://dx.doi.org/10.12677/acm.2022.12101340.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

G. Ranieri and G. Gasparini. "Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy." Current Drug Target - Immune, Endocrine & Metabolic Disorders 1, no. 3 (November 1, 2001): 241–53. http://dx.doi.org/10.2174/1568008013341073.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Catanzaro, Elena, Cinzia Calcabrini, Eleonora Turrini, Piero Sestili, and Carmela Fimognari. "Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?" Expert Opinion on Therapeutic Targets 21, no. 8 (July 10, 2017): 781–93. http://dx.doi.org/10.1080/14728222.2017.1351549.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Kuriakose, Robin K., Rakesh C. Kukreja, and Lei Xi. "Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs." Oxidative Medicine and Cellular Longevity 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/8139861.

Повний текст джерела

Анотація:

Despite their recognized cardiotoxic effects, anthracyclines remain an essential component in many anticancer regimens due to their superior antitumor efficacy. Epidemiologic data revealed that about one-third of cancer patients have hypertension, which is the most common comorbidity in cancer registries. The purpose of this review is to assess whether anthracycline chemotherapy exacerbates cardiotoxicity in patients with hypertension. A link between hypertension comorbidity and anthracycline-induced cardiotoxicity (AIC) was first suggested in 1979. Subsequent preclinical and clinical studies have supported the notion that hypertension is a major risk factor for AIC, along with the cumulative anthracycline dosage. There are several common or overlapping pathological mechanisms in AIC and hypertension, such as oxidative stress. Current evidence supports the utility of cardioprotective modalities as adjunct treatment prior to and during anthracycline chemotherapy. Several promising cardioprotective approaches against AIC pathologies include dexrazoxane, early hypertension management, and dietary supplementation of nitrate with beetroot juice or other medicinal botanical derivatives (e.g., visnagin and Danshen), which have both antihypertensive and anti-AIC properties. Future research is warranted to further elucidate the mechanisms of hypertension and AIC comorbidity and to conduct well-controlled clinical trials for identifying effective clinical strategies to improve long-term prognoses in this subgroup of cancer patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Alshehri, Mohammed M., Javad Sharifi-Rad, Jesús Herrera-Bravo, Evelyn L. Jara, Luis A. Salazar, Dorota Kregiel, Yadav Uprety, et al. "Therapeutic Potential of Isoflavones with an Emphasis on Daidzein." Oxidative Medicine and Cellular Longevity 2021 (September 9, 2021): 1–15. http://dx.doi.org/10.1155/2021/6331630.

Повний текст джерела

Анотація:

Daidzein is a phytoestrogen isoflavone found in soybeans and other legumes. The chemical composition of daidzein is analogous to mammalian estrogens, and it could be useful with a dual-directional purpose by substituting/hindering with estrogen and estrogen receptor (ER) complex. Hence, daidzein puts forth shielding effects against a great number of diseases, especially those associated with the control of estrogen, such as breast cancer, diabetes, osteoporosis, and cardiovascular disease. However, daidzein also has other ER-independent biological activities, such as oxidative damage reduction acting as an antioxidant, immune regulator as an anti-inflammatory agent, and apoptosis regulation, directly linked to its potential anticancer effects. In this sense, the present review is aimed at providing a deepen analysis of daidzein pharmacodynamics and its implications in human health, from its best-known effects alleviating postmenopausal symptoms to its potential anticancer and antiaging properties.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Kumar, Rajnish, Chanchal Singh, Avijit Mazumder, Salahuddin, Md Mustaqeem Abdullah, Vivek Kumar, and Pavan Prakash Giri. "Synthetic Approach to Potential Anticancer Benzimidazole Derivatives: A Review." Mini-Reviews in Medicinal Chemistry 22, no. 9 (May 2022): 1289–304. http://dx.doi.org/10.2174/1389557521666211001122118.

Повний текст джерела

Анотація:

Abstract: Cancer is one of the deadliest diseases in many developed and developing countries. Continuous efforts are required for designing better therapeutic agents for the treatment of cancer with more efficacy, selectivity, and less toxicity. The fused heterocyclic ring system has been identified by several researchers as a privileged structure that can be used as the basis for drug discovery in medicinal chemistry. The hetero-aromatic bicyclic ring system acts as a pharmacophore in a wide range of drugs with therapeutic potential. According to studies in the literature, various substituted benzimidazoles have distinct pharmacological profiles with multi-targeting ability, making them an important anchor for the production of novel therapeutic agents against complex cancers, including breast cancer, skin cancer, and blood cancer. In this article, we have discussed various synthetic methods for the synthesis of anti-cancer benzimidazoles and their derivatives in different solvent conditions, substrates, and various catalysts, mainly those which are eco-friendly and economical. We also focused on various derivatives those are under clinical trials containing benzimidazole moiety.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Jin, Jun-O., Pallavi Singh Chauhan, Ananta Prasad Arukha, Vishal Chavda, Anuj Dubey, and Dhananjay Yadav. "The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles." Marine Drugs 19, no. 5 (May 10, 2021): 265. http://dx.doi.org/10.3390/md19050265.

Повний текст джерела

Анотація:

Several types of cancers share cellular and molecular behaviors. Although many chemotherapy drugs have been designed to weaken the defenses of cancer cells, these drugs may also have cytotoxic effects on healthy tissues. Fucoidan, a sulfated fucose-based polysaccharide from brown algae, has gained much attention as an antitumor drug owing to its anticancer effects against multiple cancer types. Among the anticancer mechanisms of fucoidan are cell cycle arrest, apoptosis evocation, and stimulation of cytotoxic natural killer cells and macrophages. Fucoidan also protects against toxicity associated with chemotherapeutic drugs and radiation-induced damage. The synergistic effect of fucoidan with existing anticancer drugs has prompted researchers to explore its therapeutic potential. This review compiles the mechanisms through which fucoidan slows tumor growth, kills cancer cells, and interacts with cancer chemotherapy drugs. The obstacles involved in developing fucoidan as an anticancer agent are also discussed in this review.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Fakhri, Sajad, Sadaf Abdian, Seyed Zachariah Moradi, Blake E. Delgadillo, Carmela Fimognari, and Anupam Bishayee. "Marine Compounds, Mitochondria, and Malignancy: A Therapeutic Nexus." Marine Drugs 20, no. 10 (September 30, 2022): 625. http://dx.doi.org/10.3390/md20100625.

Повний текст джерела

Анотація:

The marine environment is important yet generally underexplored. It contains new sources of functional constituents that can affect various pathways in food processing, storage, and fortification. Bioactive secondary metabolites produced by marine microorganisms may have significant potential applications for humans. Various components isolated from disparate marine microorganisms, including fungi, microalgae, bacteria, and myxomycetes, showed considerable biological effects, such as anticancer, antioxidant, antiviral, antibacterial, and neuroprotective activities. Growing studies are revealing that potential anticancer effects of marine agents could be achieved through the modulation of several organelles. Mitochondria are known organelles that influence growth, differentiation, and death of cells via influencing the biosynthetic, bioenergetic, and various signaling pathways related to oxidative stress and cellular metabolism. Consequently, mitochondria play an essential role in tumorigenesis and cancer treatments by adapting to alterations in environmental and cellular conditions. The growing interest in marine-derived anticancer agents, combined with the development and progression of novel technology in the extraction and cultures of marine life, led to revelations of new compounds with meaningful pharmacological applications. This is the first critical review on marine-derived anticancer agents that have the potential for targeting mitochondrial function during tumorigenesis. This study aims to provide promising strategies in cancer prevention and treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Hasan, Mohammad Raghibul, Bader Saud Alotaibi, Ziyad Mohammed Althafar, Ahmed Hussain Mujamammi, and Jafar Jameela. "An Update on the Therapeutic Anticancer Potential of Ocimum sanctum L.: “Elixir of Life”." Molecules 28, no. 3 (January 25, 2023): 1193. http://dx.doi.org/10.3390/molecules28031193.

Повний текст джерела

Анотація:

In most cases, cancer develops due to abnormal cell growth and subsequent tumour formation. Due to significant constraints with current treatments, natural compounds are being explored as potential alternatives. There are now around 30 natural compounds under clinical trials for the treatment of cancer. Tulsi, or Holy Basil, of the genus Ocimum, is one of the most widely available and cost-effective medicinal plants. In India, the tulsi plant has deep religious and medicinal significance. Tulsi essential oil contains a valuable source of bioactive compounds, such as camphor, eucalyptol, eugenol, alpha-bisabolene, beta-bisabolene, and beta-caryophyllene. These compounds are proposed to be responsible for the antimicrobial properties of the leaf extracts. The anticancer effects of tulsi (Ocimum sanctum L.) have earned it the title of “queen of herbs” and “Elixir of Life” in Ayurvedic treatment. Tulsi leaves, which have high concentrations of eugenol, have been shown to have anticancer properties. In a various cancers, eugenol exerts its antitumour effects through a number of different mechanisms. In light of this, the current review focuses on the anticancer benefits of tulsi and its primary phytoconstituent, eugenol, as apotential therapeutic agent against a wide range of cancer types. In recent years, tulsi has gained popularity due to its anticancer properties. In ongoing clinical trials, a number of tulsi plant compounds are being evaluated for their potential anticancer effects. This article discusses anticancer, chemopreventive, and antioxidant effects of tulsi.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Palkina, Kseniia A., Daria A. Ipatova, Ekaterina S. Shakhova, Anastasia V. Balakireva, and Nadezhda M. Markina. "Therapeutic Potential of Hispidin—Fungal and Plant Polyketide." Journal of Fungi 7, no. 5 (April 22, 2021): 323. http://dx.doi.org/10.3390/jof7050323.

Повний текст джерела

Анотація:

There is a large number of bioactive polyketides well-known for their anticancer, antibiotic, cholesterol-lowering, and other therapeutic functions, and hispidin is among them. It is a highly abundant secondary plant and fungal metabolite, which is investigated in research devoted to cancer, metabolic syndrome, cardiovascular, neurodegenerative, and viral diseases. This review summarizes over 20 years of hispidin studies of its antioxidant, anti-inflammatory, anti-apoptotic, antiviral, and anti-cancer cell activity.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Dong, Wenjuan, Hu Wang, Hailin Liu, Chunqiao Zhou, Xuelin Zhang, Song Wang, and Lin He. "Potential of Black Phosphorus in Immune-Based Therapeutic Strategies." Bioinorganic Chemistry and Applications 2022 (July 11, 2022): 1–18. http://dx.doi.org/10.1155/2022/3790097.

Повний текст джерела

Анотація:

Black phosphorus (BP) consists of phosphorus atoms, an essential element of bone and nucleic acid, which covalently bonds to three adjacent phosphorus atoms to form a puckered bilayer structure. With its anisotropy, band gap, biodegradability, and biocompatibility properties, BP is considered promising for cancer therapy. For example, BP under irradiation can convert near-infrared (NIR) light into heat and reactive oxygen species (ROS) to damage cancer cells, called photothermal therapy (PTT) and photodynamic therapy (PDT). Compared with PTT and PDT, the novel techniques of sonodynamic therapy (SDT) and photoacoustic therapy (PAT) exhibit amplified ROS generation and precise photoacoustic-shockwaves to enhance anticancer effect when BP receives ultrasound or NIR irradiation. Based on the prospective phototherapy, BP with irradiation can cause a “double-kill” to tumor cells, involving tumor-structure damage induced by heat, ROS, and shockwaves and a subsequent anticancer immune response induced by in situ vaccines construction in tumor site, which is referred to as photoimmunotherapy (PIT). In conclusion, BP shows promise in natural antitumor biological activity, biological imaging, drug delivery, PTT/PDT/SDT/PAT/PIT, nanovaccines, nanoadjuvants, and combination immunotherapy regimens.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Liubota, R. V., Zh P. Yakovets, R. I. Vereshchako, M. F. Anikusko, and I. I. Liubota. "Clinical significance of anticancer vaccines (literature review)." Practical oncology 4, no. 2 (August 19, 2021): 14–24. http://dx.doi.org/10.22141/2663-3272.4.2.2021.238669.

Повний текст джерела

Анотація:

During the past few decades, the advances in cancer immunotherapy have revived interest in the potential use of vaccines for the malignant tumor treatment. Tumor-associated antigens, which are abnormally expressed by tumor cells, are of decisive importance in the development of anticancer vaccines. Through the stimulation of immunological memory, therapeutic anticancer vaccines can result in long-term remission or healing patients. Therapeutic anticancer vaccines due to the potential safety, specificity and duration of effect can become an alternative to or increase the effectiveness of existing immunotherapies. This article presents data on the tumor antigen structure, characteristics of anticancer vaccines and the results of studies on the clinical efficacy of anticancer vaccines.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Jo, Hyein, Kyeonghee Shim, and Dooil Jeoung. "The Potential of Senescence as a Target for Developing Anticancer Therapy." International Journal of Molecular Sciences 24, no. 4 (February 8, 2023): 3436. http://dx.doi.org/10.3390/ijms24043436.

Повний текст джерела

Анотація:

Senescence occurs in response to various stimuli. Senescence has attracted attention because of its potential use in anticancer therapy as it plays a tumor-suppressive role. It also promotes tumorigeneses and therapeutic resistance. Since senescence can induce therapeutic resistance, targeting senescence may help to overcome therapeutic resistance. This review provides the mechanisms of senescence induction and the roles of the senescence-associated secretory phenotype (SASP) in various life processes, including therapeutic resistance and tumorigenesis. The SASP exerts pro-tumorigenic or antitumorigenic effects in a context-dependent manner. This review also discusses the roles of autophagy, histone deacetylases (HDACs), and microRNAs in senescence. Many reports have suggested that targeting HDACs or miRNAs could induce senescence, which, in turn, could enhance the effects of current anticancer drugs. This review presents the view that senescence induction is a powerful method of inhibiting cancer cell proliferation.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Matos, Cristina P., Yasemin Yildizhan, Zelal Adiguzel, Fernando R. Pavan, Débora L. Campos, João Costa Pessoa, Liliana P. Ferreira, Ana Isabel Tomaz, Isabel Correia, and Ceyda Acilan. "New ternary iron(iii) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents." Dalton Transactions 48, no. 24 (2019): 8702–16. http://dx.doi.org/10.1039/c9dt01193e.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Therapeutic potential of anticancer immunotoxins"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями